- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02518581
Validation of the Doubly Labelled Water Method in Subjects With Type 2 Diabetes Mellitus (DLW)
Estimating Free-living Human Energy Expenditure - Validation of the Doubly Labelled Water Method in Subjects With Type 2 Diabetes Mellitus
The present study is an exploratory trial to establish a feasible DLW (doubly labelled water) protocol for implementation in clinical trials conducted at Profil Institut für Stoffwechselforschung, investigating treatment options for overweight and obesity in populations with and without diabetic comorbidity. The study aims at the practical validation of a 1-2-week DLW protocol in overweight and obese type 2 diabetic subjects.
Total Energy Expenditure (TEE) values as assessed by DLW will then be compared to (1) TEE as calculated based on individual anthropometric measurements (including body composition) using the Müller formula and the AEE (activity related energy expenditure) based on reported work place and leisure time activities and (2) TEE as calculated from measured REE (resting energy expenditure) as assessed by indirect calorimetry and the AEE based on information recorded by the subjects in a physical activity diary and corresponding pedometer counts. Moreover, TEE assessments will be repeated once (separated by 2-4 weeks) to determine intra-subject variability / re-test reliability of the measurement.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Neuss, Germany, 41460
- Profil Institut für Stoffwechselforschung GmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent obtained before any trial-related activities.
- Stable weight +/- 5% for at least 3 months prior screening visit.
- Male or female subject, 18-64 years of age, both inclusive.
- Body Mass Index (BMI) >= 25 kg/m2.
- Type 2 diabetes mellitus (as diagnosed clinically) ≥ 12 months.
- HbA1c <= 9 % at screening visit.
Stable treatment (>= 3 month) with
- Oral antidiabetics (OADs) (except OADs that are associated with a reduction in body weight (α-glucosidase inhibitors, sodium glucose transporter 2-inhibitors (SGLT2))) and/or
- basal insulin injections and/or
- a dietary regimen. Subjects on a basal-bolus insulin regimen will not be enrolled.
- Considered generally healthy (apart from type 2 diabetes mellitus and with the exception of conditions associated with diabetes mellitus or the metabolic syndrome, such as dyslipidaemia and hypertension) upon completion of medical history, physical examination, vital signs, and analysis of laboratory safety variables, as judged by the Investigator.
Exclusion Criteria:
- Clinical significant acute illness within 2 weeks before study procedures, including severe infections, as judged by the Investigator.
- Receipt of any investigational medicinal product within 3 months before trial related procedures.
- Mental incapacity or language barriers which preclude adequate understanding or cooperation, unwillingness to participate in the trial, known or suspected not to comply with study directives or not to be reliable or trustworthy, or subjects who in the opinion of their general practitioner or the Investigator should not participate in the trial.
- Use of diuretics.
- Intake of any other drug or dietary supplement that in the opinion of the Investigator may impair validity of energy expenditure assessments.
- Clinically significant abnormal biochemistry screening tests, as judged by the Investigator. In particular, elevated liver enzymes (AST or ALT > 3 times the upper limit of normal) or impaired renal function with an estimated Glomerular Filtration Rate (eGFR; estimate after CKD-EP) < 60 ml/min.
- Clinically significant abnormal electrocardiogram (ECG) findings at screening, as judged by the Investigator.
- Positive alcohol breath test at screening visit.
- Significant history of alcoholism or drug abuse as judged by the Investigator or consuming more than 21 units of alcohol per week (one unit of alcohol equals about 330 ml of beer, one glass of wine of 120 ml, or 40 ml spirits).
- Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day) who is not able or willing to refrain from smoking and use of nicotine substitute products during the study.
- Excessive consumption of coffee and tea (i.e. more than 5 cups/day), chocolate or beverages such as cola containing methylxanthine (caffeine, theophylline or theobromine) as judged by the investigator.
- Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures include surgical sterilisation, hormonal intrauterine devices (coil), oral hormonal contraceptives, sexual abstinence or a surgically sterilised partner).
- Type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or secondary forms of diabetes, e.g., acromegaly or Cushing's syndrome.
- History of hyperosmolar crisis, diabetic coma, or severe hypoglycemia within the last 3 months prior to trial examinations.
- Use of weight-loss medication or any non-permitted antidiabetic medication that is associated with a reduction in body weight (α-glucosidase inhibitors, SGLT2-inhibitors) within 3 months before trial examination.
- Use of injectable anti-diabetic therapy (other than insulin), e.g. GLP-1 receptor agonists (glucagon-like peptide), within 3 months prior to screening.
- Steroid therapy other than topical application.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Doubly labelled water
|
DLW (doubly labeled water) method measures isotope dilution spaces and elimination rates to assess total energy expenditure (TEE).
After enriching the body water of a subject with DLW (2H and 18O), it is only necessary to collect urine samples at defined time points, usually over a period of 1-2 weeks, so that the measurement can be done in individuals able to engage in their typical habits without restrictions.
The resulting TEE measurement represents an integral value over the measurement period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Free-living total energy expenditure
Time Frame: up to 3 month
|
Assessed by doubly labelled water
|
up to 3 month
|
Resting energy expenditure
Time Frame: up to 3 month
|
Assessed by indirect calorimetry
|
up to 3 month
|
Activity-induced energy expenditure
Time Frame: up to 3 month
|
Assessed by diary and pedometer
|
up to 3 month
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OBDM-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
Clinical Trials on Doubly labelled water method
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceCompletedCongestive Heart FailureFrance
-
East and North Hertfordshire NHS TrustUniversity of HertfordshireCompletedKidney Diseases | Chronic Kidney Diseases
-
University of Wisconsin, MilwaukeeNational Cancer Institute (NCI); University of Colorado, Denver; University of...RecruitingMovement Disorders | Energy MetabolismUnited States
-
Institut National de Recherche pour l'Agriculture...Centre de Recherche en Nutrition Humaine Rhone-Alpe; Centre de Recherche en...CompletedEnergy Expenditure | Computer Simulation | Energy MetabolismFrance
-
Pennington Biomedical Research CenterCompleted
-
VA Office of Research and DevelopmentCompletedColorectal NeoplasmsUnited States
-
Gadjah Mada UniversityCompletedColonoscopy Diagnostic Techniques and ProceduresIndonesia
-
Presidio Ospedaliero Santa BarbaraCompletedPain | Colorectal Cancer | Colorectal Polyps | Colorectal AdenomasUnited States, Czech Republic, Italy
-
Presidio Ospedaliero Santa BarbaraCompletedPain | Colorectal Cancer | Colorectal AdenomasUnited States, Italy
-
Presidio Ospedaliero Santa BarbaraCompletedPain | Colorectal Cancer | Colorectal AdenomasUnited States, Italy